Aurora Cannabis Inc (ACB) Rating Reaffirmed
This Morning, Cowen Co. restate their Buy rating on Aurora Cannabis Inc (ACB) shares in an analyst report issued.
The stock decreased 0.83% or $0.07 during the last trading session, reaching $8.99. About 13.02M shares traded. Aurora Cannabis Inc. (ACB) has declined 10.79% since March 14, 2018 and is downtrending. It has underperformed by 15.16% the SP500.
Analysts await Aurora Cannabis Inc. (NYSE:ACB) to report earnings on May, 14. They expect $-0.05 EPS, down 25.00 % or $0.01 from last year’s $-0.04 per share. After $-0.04 actual EPS reported by Aurora Cannabis Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.
Aurora Cannabis Inc. produces and distributes medical cannabis products. The company has market cap of $9.05 billion. It is vertically integrated and horizontally diversified across various divisions of the cannabis value chain,